Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy

Condition(s) studied

Investigational drug(s) / intervention(s)

Immunotherapeutic Agent: Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.

Molecular Target: Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.

Study summary

The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank. Targeted individuals are cancer patients of all types, treated with immunotherapy or targeted therapy.

Immunotherapy or targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.

With the aim to identify predictive markers of response to treatment or possible resistance mechanism, the plasma samples and the tumor samples will be used for genetic analysis, for example but not limited to, whole exome sequencing. This may lead to the discovery of some germinal mutations implicated in other diseases than cancer.

Eligibility

Primary outcome measure(s)

• efficacy of treatment against Cancer — From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
  Efficacy will be determined in terms of overall responses according to standard practice by the local investigator. Disease and response assessments are defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Trial sites (1)

More Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials in Belgium

Other trials for the same condition